Pesquisa nas coleções internacionais e nacionais de patentes
Algum conteúdo deste aplicativo está indisponível no momento.
Se esta situação persistir, por favor entre em contato conoscoFale conosco & Contato
1. (WO1992010493) POLYMORPHS OF CRYSTALLINE MUPIROCIN
Nota: O texto foi obtido por processos automáticos de reconhecimento ótico de caracteres.
Para fins jurídicos, favor utilizar a versão PDF.

Claims

1. A crystalline mupirocin polymorph (FORM III) having a melting point in the range 82.5-86°C and characterised by an

5 X-ray powder diffractogram substantially as shown in
accompanying Fig.3.

2. A crystalline mupirocin polymorph (FORM II) having a melting point in the range 67-77°C and characterised by an

10 X-ray powder diffractogram substantially as shown in
accompanying Fig.2.

3. A crystalline mupirocin polymorph according to claim 1 further characterised by an IR spectrum substantially as

15 shown in accompanying Fig.6.

4. A crystalline mupirocin polymorph according to claim 2 further characterised by an IR spectrum substantially as shown in accompanying Fig.7.
20
5. A process for preparing a crystalline mupirocin polymorph (FORM III) as defined in claim 1 which comprises recrystallizing mupirocin from a solution of mupirocin in an organic solvent (or solvent mixture) while maintaining the

25 temperature at 40°C or above.

6. A process according to claim 5 in which the organic solvent has a water content of less than 0.1% w/v.

307. A process according to claim 5 or 6 in which the initially formed crystalline precipitate is stirred while maintaining the temperature at 40°C or above until the crystalline precipitate is substantially all FORM III.

358. A process according to claim 5 substantially as described in Examples 2 or 3.

9. A process for preparing a crystalline mupirocin polymorph (FORM II) as defined in claim 2 comprising
precipitating mupirocin from a solution of mupirocin in an organic solvent containing water by addition of another

5 organic solvent, and allowing the resultant oil to solidify.

10. A process according to claim 9 in which the solvent has a water content of 1-1.5% w/v.

10 11. A process according to claim 9 or 10 in which the oil is stirred until solidification takes place.

12. A process according to claim 9 substantially as described in Example 1.
5
13. A mixture of mupirocin polymorphs that contains at least 90% by weight of the polymorph of claim 1.

14. A mixture of mupirocin polymorphs that contains at 0 least 90% by weight of the polymorph of claim 2.

15. A pharmaceutical or veterinary composition comprising mupirocin polymorphs of claim 1 or 2 or a polymorph mixture of claim 13 or 14 together with a pharmaceutically or
5 veterinarially acceptable carrier.

16. A composition according to claim 15 comprising from 1 to 3% of mupirocin polymorph, from 65 to 96% of white soft paraffin, from 0 to 15% of liquid paraffin and from 3 to 7% 0 of lanolin or a derivative or synthetic equivalent thereof.

17. A composition according to claim 15 comprising from 1 to 3% of mupirocin polymorph, from 25 to 60% of liquid paraffin, from 20 to 50% of water and from 3 to 30% of emulsifier.

18. A mupirocin polymorph or polymorph mixture as defined in any one of claims 1,2,13 or 14, for use in anti-infective

5 therapy.

19. A mupirocin polymorph or polymorph mixture as defined in any one of claims 1,2,13 or 14, for use in anti-infective therapy.
10
20. A mupirocin polymorph or polymorph mixture as claimed in any one of claims 1,2,13 or 14, for use as a growth promoter in animals .

1521. A veterinarily acceptable premix formulation
comprising a mupirocin polymorph or polymorph mixture as defined in any one of claims 1,2,13 or 14 in association with a veterinarily acceptable carrier.

2022. A method of combatting bacterial or fungal infections in humans or animals which comprises administering an effective amount of a mupirocin polymorph or polymorph mixture as defined in any one of claims 1,2,13 or 14 to an infected human or animal.
25
23. The use of a mupirocin polymorph or polymorph mixture as defined in any one of claims 1,2,13 or 14, for the manufacture of a medicament for the treatment. of infections.